ENGN: financial statements from SEC — TradeAlmanac

ENGN

enGene Therapeutics Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Apr 30, 2026	Jan 31, 2026	Jul 31, 2025	Apr 30, 2025	Jan 31, 2025	Jul 31, 2024
Research and development	22m	22m	23m	20m	20m	12m
Selling, general and administrative	10m	9m	7m	7m	7m	5m
Operating expenses	32m	31m	30m	27m	27m	17m
Operating income	−32m	−31m	−30m	−27m	−27m	−17m
Pre-tax income	−30m	−30m	−29m	−26m	−25m	−14m
Income tax	0	0	239,000	240,000	18,000	−29,000
Net income	−30m	−30m	−29m	−26m	−25m	−14m
Earnings per share	−0.43	0.44	0.57	0.51	0.48	0.32
Earnings per share, diluted	−0.43	0.44	0.57	0.51	0.48	0.32
Weighted average shares	70m	67m	51m	51m	51m	44m
Weighted average shares, diluted	70m	67m	51m	51m	51m	44m

Balance sheet

Metric	Apr 30, 2026	Jan 31, 2026	Oct 31, 2025	Jul 31, 2025	Apr 30, 2025	Jan 31, 2025	Oct 31, 2024	Jul 31, 2024
Cash and equivalents	30m	37m	50m	33m	58m	62m	173m	258m
Short-term investments	229m	239m

Cash flow

Metric	Jan 31, 2026	Jan 31, 2025
Operating cash flow	−29m	−26m
Depreciation and amortisation	189,000	102,000
Share-based compensation	3m	2m
Capital expenditure	153,000	299,000
Investing cash flow	−126m	−85m
Financing cash flow	142m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)